thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 17, 2026

Commit raises $60 million to advance complement immunotherapy

The seed round will fund preclinical work and regulatory preparations for COM002, which the company plans to take into clinical trials.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

Commit Biologics raised $60 million in a seed round led by Ackermans & van Haaren, with Novo Holdings, Bioqube Ventures and Korys participating and AbbVie Ventures and M Ventures joining its shareholder base.1 The company plans to prepare COM002 for clinical testing and aims to dose its first patient in early 2028.1

Commit raises $60 million for COM002

Commit Biologics raised $60 million to advance COM002, its complement-based immunotherapy candidate.1 Ackermans & van Haaren led the seed round. Existing investors Novo Holdings, Bioqube Ventures and Korys also participated.1 AbbVie Ventures and M Ventures joined the company’s shareholder base through the financing.1

Commit said it will use the proceeds for studies needed before clinical testing and to prepare regulatory filings for COM002.1 The company aims to dose its first patient in early 2028.1

Commit reported that COM002 depleted B cells more effectively than an approved T-cell engager in human whole-blood experiments.1 In a separate nonhuman-primate study, one dose kept B-cell depletion going for more than four weeks, with no cytokine release or treatment-related safety findings reported by the company.1 These findings are preclinical and do not establish how the candidate will perform or whether it will be safe in patients.1